Regulation Of Biologics Serialization And Anti-Counterfeiting Rules Germany

Introduction

Biologics serialization and anti-counterfeiting regulations are designed to protect patients against falsified, stolen, tampered or improperly distributed biological medicinal products. Biologics include vaccines, monoclonal antibodies, blood-derived medicines, recombinant proteins and gene therapy products. These medicines require strict quality controls because their biological composition can make them sensitive to contamination, temperature changes and manufacturing defects.

Germany follows the European Union's pharmaceutical safety framework, particularly the Falsified Medicines Directive 2011/62/EU, Commission Delegated Regulation (EU) 2016/161 and the German Medicinal Products Act (Arzneimittelgesetz – AMG). These rules establish product identification, verification and packaging-security requirements throughout the pharmaceutical supply chain.

Legal Framework Governing Serialization

1. Falsified Medicines Directive 2011/62/EU

The Falsified Medicines Directive amended Directive 2001/83/EC to strengthen controls against falsified medicinal products entering the legitimate pharmaceutical supply chain.

Article 54a of Directive 2001/83/EC establishes safety-feature requirements for specified medicinal products. These features generally include:

A unique identifier allowing individual medicine packs to be identified and authenticated.

An anti-tampering device showing whether the outer packaging has been opened or altered.

The requirements apply to medicines falling within the relevant categories established by EU legislation. Not every biological medicine automatically has identical serialization obligations; applicability depends on the product's classification and the relevant exemptions.

2. Commission Delegated Regulation (EU) 2016/161

Commission Delegated Regulation (EU) 2016/161 establishes detailed technical requirements for safety features.

The unique identifier generally contains:

Product code.

Serial number.

National reimbursement or identification number, where applicable.

Batch number.

Expiry date.

The identifier is generally represented through a two-dimensional Data Matrix code. It allows authorised supply-chain participants to verify the authenticity of a medicine pack.

The anti-tampering device provides an additional physical safeguard by indicating whether the packaging has been opened or interfered with.

German Serialization System: securPharm

Germany implements the EU medicines-verification framework through securPharm, its national medicines verification system.

The system connects pharmaceutical manufacturers, wholesalers, pharmacies and other authorised stakeholders with a national verification repository linked to the European medicines verification system.

Its principal functions include:

Uploading unique identifiers for qualifying medicine packs.

Verifying product authenticity before dispensing.

Checking whether a product identifier has already been decommissioned.

Detecting possible falsification or unauthorised reuse.

Supporting investigations into suspicious pharmaceutical products.

Under the applicable rules, pharmacies generally verify and decommission the unique identifier when supplying qualifying medicines to patients. Certain other authorised supply-chain participants must also perform verification or decommissioning in specified circumstances.

The system is designed to prevent falsified products from reaching patients through legitimate distribution channels.

Requirements Under the German Medicinal Products Act

The German Medicinal Products Act (AMG) establishes national requirements concerning medicinal-product manufacturing, authorisation, distribution and supervision.

Section 13 AMG generally requires manufacturing authorisation for medicinal-product manufacturing activities, subject to statutory exceptions.

Section 19 AMG concerns the responsibilities of the qualified person for ensuring that medicinal products comply with applicable manufacturing and testing requirements before release.

Section 52a AMG regulates authorisation for wholesale distribution of medicinal products.

These provisions complement EU serialization requirements by ensuring that manufacturing and distribution activities are conducted by authorised organisations.

Manufacturers and wholesalers must also maintain appropriate documentation, product records and quality-control systems. Where a falsified or defective biological medicine is identified, the relevant organisations may need to notify competent authorities and cooperate in product investigations or recalls.

Special Considerations for Biological Medicinal Products

Biological medicines require additional quality and supply-chain safeguards because they may be sensitive to temperature, handling and contamination.

Manufacturers and distributors must follow applicable Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) requirements.

Important controls include:

Batch identification and manufacturing records.

Temperature-controlled transportation where required.

Monitoring of storage conditions.

Documentation of distribution transactions.

Investigation of packaging irregularities.

Procedures for product recalls and quality defects.

For biologics, serialization helps identify individual medicine packs, while batch traceability allows manufacturers and regulators to investigate quality problems affecting a particular production batch.

Regulatory Authorities and Enforcement

Several institutions participate in enforcement:

1. Federal Institute for Drugs and Medical Devices (BfArM): Supervises medicinal products within its statutory responsibilities and participates in measures against falsified medicines.

2. Paul-Ehrlich-Institut (PEI): Has important responsibilities concerning vaccines, blood products and other biological medicinal products.

3. State authorities: German Länder authorities supervise many manufacturing and distribution activities, including inspections of pharmaceutical establishments.

4. European Medicines Agency (EMA): Coordinates scientific and regulatory activities concerning centrally authorised medicines and cooperates with national authorities.

Violations may result in administrative measures, suspension of activities, product recalls and criminal consequences where the statutory requirements for an offence are satisfied.

Relevant Case Laws

There is no leading German court judgment specifically deciding the technical requirements of biologics serialization under securPharm. However, the following Court of Justice of the European Union decisions provide relevant pharmaceutical regulatory principles.

1. Bristol-Myers Squibb and Others v Paranova (Joined Cases C-427/93, C-429/93 and C-436/93, 1996)

The Court examined the repackaging of medicinal products in parallel trade. It established conditions under which repackaging may be permitted while protecting public health and trademark rights. The decision is relevant to packaging integrity and the identification of medicines during distribution.

2. Ferring Arzneimittel GmbH v Eurim-Pharm Arzneimittel GmbH (Case C-172/00, 2002)

The Court considered pharmaceutical distribution and parallel trade. The judgment is relevant to the movement of medicinal products within the EU and the regulatory responsibilities associated with distribution.

3. Aventis Pharma Deutschland GmbH v Kohlpharma GmbH (Case C-348/04, 2006)

The Court considered pharmaceutical repackaging and the conditions governing parallel distribution. Its reasoning supports the importance of maintaining product identification and protecting patients when medicines are repackaged or distributed across national markets.

4. Ferring Lægemidler A/S v Orifarm A/S (Case C-297/15, 2016)

The Court examined the repackaging of medicinal products in parallel trade and the conditions under which such activity may be justified. The decision is relevant to packaging protection and the integrity of medicinal-product distribution.

These judgments concern pharmaceutical distribution and packaging rather than the securPharm database itself.

Conclusion

Germany regulates biologics serialization and anti-counterfeiting through the Falsified Medicines Directive, Delegated Regulation (EU) 2016/161, the AMG and the securPharm verification system. Qualifying medicinal-product packages must carry appropriate safety features, including unique identifiers and anti-tampering devices. Manufacturers, wholesalers and pharmacies have defined responsibilities for verification, documentation and product handling. Additional GMP and GDP requirements protect the quality of biological medicines during manufacturing and distribution. Together, these rules strengthen pharmaceutical supply-chain security and reduce the risk of falsified biologics reaching patients.